Predictors of survival in patients with advanced hepatocellular carcinoma who permanently discontinued sorafenib

Massimo Iavarone, Giuseppe Cabibbo, Marco Biolato, Cristina Della Corte, Marcello Maida, Marco Barbara, Michele Basso, Sara Vavassori, Antonio Craxì, Antonio Grieco, Carlo Cammà, Massimo Colombo

Research output: Contribution to journalArticle

Abstract

Treatment with sorafenib of patients with advanced hepatocellular carcinoma is challenged by anticipated discontinuation due to tumor progression, liver decompensation, or adverse effects. While postprogression survival is clearly determined by the pattern of tumor progression, understanding the factors that drive prognosis in patients who discontinued sorafenib for any reason may help to improve patient management and second-line trial design. Patients consecutively admitted to three referral centers who were receiving best supportive care following permanent discontinuation of sorafenib for any reason were included. Postsorafenib survival (PSS) was calculated from the last day of treatment to death or last visit available. Two hundred and sixty patients were included in this prospective study, aged 67 years, 60% with hepatitis C, 51% Child-Pugh A, 83% performance status (PS) ≥1, 41% with macroscopic vascular invasion, and 38% with extrahepatic tumor spread. Overall, median PSS was 4.1 (3.3-4.9) months, resulting from 4.6 (3.3-5.7) months for 123 progressors, 7.3 (6.0-10.0) months in 77 with adverse effects, and 1.8 (1.6-2.4) months in 60 decompensated patients (P

Original languageEnglish
Pages (from-to)784-791
Number of pages8
JournalHepatology
Volume62
Issue number3
DOIs
Publication statusPublished - Sep 1 2015

Fingerprint

Hepatocellular Carcinoma
Survival
Neoplasms
Hepatitis C
Blood Vessels
sorafenib
Referral and Consultation
Prospective Studies
Liver
Therapeutics

ASJC Scopus subject areas

  • Hepatology
  • Medicine(all)

Cite this

Predictors of survival in patients with advanced hepatocellular carcinoma who permanently discontinued sorafenib. / Iavarone, Massimo; Cabibbo, Giuseppe; Biolato, Marco; Della Corte, Cristina; Maida, Marcello; Barbara, Marco; Basso, Michele; Vavassori, Sara; Craxì, Antonio; Grieco, Antonio; Cammà, Carlo; Colombo, Massimo.

In: Hepatology, Vol. 62, No. 3, 01.09.2015, p. 784-791.

Research output: Contribution to journalArticle

Iavarone, M, Cabibbo, G, Biolato, M, Della Corte, C, Maida, M, Barbara, M, Basso, M, Vavassori, S, Craxì, A, Grieco, A, Cammà, C & Colombo, M 2015, 'Predictors of survival in patients with advanced hepatocellular carcinoma who permanently discontinued sorafenib', Hepatology, vol. 62, no. 3, pp. 784-791. https://doi.org/10.1002/hep.27729
Iavarone, Massimo ; Cabibbo, Giuseppe ; Biolato, Marco ; Della Corte, Cristina ; Maida, Marcello ; Barbara, Marco ; Basso, Michele ; Vavassori, Sara ; Craxì, Antonio ; Grieco, Antonio ; Cammà, Carlo ; Colombo, Massimo. / Predictors of survival in patients with advanced hepatocellular carcinoma who permanently discontinued sorafenib. In: Hepatology. 2015 ; Vol. 62, No. 3. pp. 784-791.
@article{d22b93ddc0614e3caadf14a5b8cae43c,
title = "Predictors of survival in patients with advanced hepatocellular carcinoma who permanently discontinued sorafenib",
abstract = "Treatment with sorafenib of patients with advanced hepatocellular carcinoma is challenged by anticipated discontinuation due to tumor progression, liver decompensation, or adverse effects. While postprogression survival is clearly determined by the pattern of tumor progression, understanding the factors that drive prognosis in patients who discontinued sorafenib for any reason may help to improve patient management and second-line trial design. Patients consecutively admitted to three referral centers who were receiving best supportive care following permanent discontinuation of sorafenib for any reason were included. Postsorafenib survival (PSS) was calculated from the last day of treatment to death or last visit available. Two hundred and sixty patients were included in this prospective study, aged 67 years, 60{\%} with hepatitis C, 51{\%} Child-Pugh A, 83{\%} performance status (PS) ≥1, 41{\%} with macroscopic vascular invasion, and 38{\%} with extrahepatic tumor spread. Overall, median PSS was 4.1 (3.3-4.9) months, resulting from 4.6 (3.3-5.7) months for 123 progressors, 7.3 (6.0-10.0) months in 77 with adverse effects, and 1.8 (1.6-2.4) months in 60 decompensated patients (P",
author = "Massimo Iavarone and Giuseppe Cabibbo and Marco Biolato and {Della Corte}, Cristina and Marcello Maida and Marco Barbara and Michele Basso and Sara Vavassori and Antonio Crax{\`i} and Antonio Grieco and Carlo Camm{\`a} and Massimo Colombo",
year = "2015",
month = "9",
day = "1",
doi = "10.1002/hep.27729",
language = "English",
volume = "62",
pages = "784--791",
journal = "Hepatology",
issn = "0270-9139",
publisher = "John Wiley and Sons Inc.",
number = "3",

}

TY - JOUR

T1 - Predictors of survival in patients with advanced hepatocellular carcinoma who permanently discontinued sorafenib

AU - Iavarone, Massimo

AU - Cabibbo, Giuseppe

AU - Biolato, Marco

AU - Della Corte, Cristina

AU - Maida, Marcello

AU - Barbara, Marco

AU - Basso, Michele

AU - Vavassori, Sara

AU - Craxì, Antonio

AU - Grieco, Antonio

AU - Cammà, Carlo

AU - Colombo, Massimo

PY - 2015/9/1

Y1 - 2015/9/1

N2 - Treatment with sorafenib of patients with advanced hepatocellular carcinoma is challenged by anticipated discontinuation due to tumor progression, liver decompensation, or adverse effects. While postprogression survival is clearly determined by the pattern of tumor progression, understanding the factors that drive prognosis in patients who discontinued sorafenib for any reason may help to improve patient management and second-line trial design. Patients consecutively admitted to three referral centers who were receiving best supportive care following permanent discontinuation of sorafenib for any reason were included. Postsorafenib survival (PSS) was calculated from the last day of treatment to death or last visit available. Two hundred and sixty patients were included in this prospective study, aged 67 years, 60% with hepatitis C, 51% Child-Pugh A, 83% performance status (PS) ≥1, 41% with macroscopic vascular invasion, and 38% with extrahepatic tumor spread. Overall, median PSS was 4.1 (3.3-4.9) months, resulting from 4.6 (3.3-5.7) months for 123 progressors, 7.3 (6.0-10.0) months in 77 with adverse effects, and 1.8 (1.6-2.4) months in 60 decompensated patients (P

AB - Treatment with sorafenib of patients with advanced hepatocellular carcinoma is challenged by anticipated discontinuation due to tumor progression, liver decompensation, or adverse effects. While postprogression survival is clearly determined by the pattern of tumor progression, understanding the factors that drive prognosis in patients who discontinued sorafenib for any reason may help to improve patient management and second-line trial design. Patients consecutively admitted to three referral centers who were receiving best supportive care following permanent discontinuation of sorafenib for any reason were included. Postsorafenib survival (PSS) was calculated from the last day of treatment to death or last visit available. Two hundred and sixty patients were included in this prospective study, aged 67 years, 60% with hepatitis C, 51% Child-Pugh A, 83% performance status (PS) ≥1, 41% with macroscopic vascular invasion, and 38% with extrahepatic tumor spread. Overall, median PSS was 4.1 (3.3-4.9) months, resulting from 4.6 (3.3-5.7) months for 123 progressors, 7.3 (6.0-10.0) months in 77 with adverse effects, and 1.8 (1.6-2.4) months in 60 decompensated patients (P

UR - http://www.scopus.com/inward/record.url?scp=84939653557&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84939653557&partnerID=8YFLogxK

U2 - 10.1002/hep.27729

DO - 10.1002/hep.27729

M3 - Article

C2 - 25645399

AN - SCOPUS:84939653557

VL - 62

SP - 784

EP - 791

JO - Hepatology

JF - Hepatology

SN - 0270-9139

IS - 3

ER -